البحث | Net Pals

EthanWalker أضاف وظيفة جديدة أخرى
2026-10-23 22:16:07 - ترجمة -

Alvotech (ALVO) files first known Eylea 8 mg biosimilar application in Europe
Alvotech and Advanz Pharma sent AVT29 to the European Medicines Agency on 14 October 2026 as a line extension to Mynzepli, the Eylea 2 mg biosimilar. Alvotech (ALVO) and its partner Advanz Pharma submitted AVT29 to the European Medicines Agency on 14 October 2026, according to a company release issued the same day. AVT29 is a proposed biosimilar to Eylea 8 mg, the higher-dose form of...

0 التعليقات 0 المشاركات 19 مشاهدة 0 معاينة

الرجاء تسجيل الدخول , للأعجاب والمشاركة والتعليق على هذا!
JamesWilson أضاف وظيفة جديدة أخرى
2026-10-23 19:43:53 - ترجمة -

Ionis (IONS) partner Roche shows sefaxersen cut IgA nephropathy proteinuria 43.1% in Phase 3
Roche gave the first effect size from its IMAgINATION kidney trial at ASN Kidney Week, a clearer read for Ionis Pharmaceuticals Inc. (IONS) on a partnered drug that carries milestones and royalties. Sefaxersen cut proteinuria by 43.1% against placebo at 37 weeks in a Phase 3 trial in IgA nephropathy, according to data Ionis Pharmaceuticals Inc. (IONS) released on October 23. Roche Holding AG,...

0 التعليقات 0 المشاركات 41 مشاهدة 0 معاينة

الرجاء تسجيل الدخول , للأعجاب والمشاركة والتعليق على هذا!
supriyamaximize أضاف وظيفة جديدة Health
2026-09-04 12:08:52 - ترجمة -

Pharmaceutical Continuous Manufacturing Market Demand, Trends and Growth Opportunities to 2030
Pharmaceutical Continuous Manufacturing Market Overview The Pharmaceutical Continuous Manufacturing Market report provides an in-depth analysis that is required to make informed industry decisions and develop strategic growth plans. Regardless of the production method or cost structures, the Pharmaceutical Continuous Manufacturing market report provides a full...

0 التعليقات 0 المشاركات 962 مشاهدة 0 معاينة

الرجاء تسجيل الدخول , للأعجاب والمشاركة والتعليق على هذا!